←
Loading live data…
$PFE$29.88 ▼3%
Pfizer Inc.
WHAT THEY DO
Pfizer is a global biopharmaceutical company that discovers, develops, manufactures and sells prescription medicines and vaccines. It makes money selling branded drugs and vaccines across oncology, internal medicine, immunology, antivirals and hospital care, plus a consumer health-adjacent portfolio.
💎 CONVERGENCE PLAY — in 2 themes
GLP-1 / ObesityOncologyPatent-Cliff Recovery
PRICE
Loading…
REVENUE MIX
Oncology25%
Primary Care / Internal Medicine30%
Specialty Care / Immunology20%
Vaccines15%
Hospital / Other10%
COST
COGS25%
R&D17%
SG&A22%
Op Margin33%
FINANCIAL HEALTH
Reported through Sep 27, 2026
Figures are trailing twelve months (TTM) unless marked otherwise.
REVENUE
$63.6B
Growth
0%
QTR YOY
Gross M.
75%
P/E
42.7
EV/EBITDA
8.8
Net M.
6%
FCF M.
20%
D/E
0.75
LATEST QTR
Op M.
33%
PLUG INTO YOUR DCF
Historical growth
8.5%
Analyst 5y growth
—
Forward P/E
10.2
PEG ratio
14.10
Trailing EPS
$0.70
Forward EPS
$2.90
Multiple compressing
Forward P/E is lower than trailing — earnings are expected to grow into the price.
CAPEX & R&D — LAST 0 FISCAL YEARS (SEC FILINGS)
Loading…
TAM
SIZE
$1.6T by 2030
CAGR
6%
Global pharmaceutical spending is projected to exceed $1.6 trillion by 2030, driven by aging populations, oncology and obesity/GLP-1 demand. Pfizer competes in large but crowded categories where pricing pressure and patent expiries offset volume growth.
RISK ASSESSMENT
HIGPost-COVID revenue cliff and patent expiries (e.g. key oncology and internal medicine franchises) erode the base faster than new launches replace it.
MEDLarge debt load from the Seagen acquisition plus thin net margin (7%) limit flexibility if pipeline or M&A disappoints.
LOWPricing and policy risk from US drug-price negotiation and international reference pricing.
🐂 BULL
Trading near 8.8x EV/EBITDA with a 75% gross margin, Pfizer is priced for stagnation; Seagen oncology ramp and cost cuts could re-rate the stock toward mid-teens multiples.
🐻 BEAR
Revenue has shrunk from $91.8B in 2022 to $62.6B in 2025, net margin is only 7%, and a 39.5x trailing P/E on depressed earnings signals the market sees little growth ahead.
EARNINGS
EPS · Q3 2026
Beat ✓
REVENUE
Miss
MANAGEMENT TONE
BearishBullish
🔗 IMPACT ON YOUR THESIS
Seagen oncology portfolio scales into a durable growth driver
Watch→Watch
Oncology growth steady but not yet enough to offset legacy declines
Cost-reduction program restores operating leverage
On Track→On Track
Margin discipline held despite soft top line
Obesity/GLP-1 pipeline optionality
Watch→Watch
No major new data; timeline unchanged
AI-powered data, computed by TreasureX · May contain inaccuracies
⚠️
All values, scores, and figures here are computed from your own assumptions and public data, for educational purposes only. This is not investment advice — TreasureX does not recommend buying or selling any security. Results change with your inputs. Please do your own research and use your own judgement before making any investment decision.